A surge in lawsuits is challenging the safety profile of widely-used diabetes and weight loss medications Ozempic, Wegovy, and Mounjaro. Patients are taking legal action against manufacturers Novo Nordisk and Eli Lilly, claiming inadequate disclosure of serious health risks, particularly severe digestive complications ranging from gastric distress to dental deterioration.
These medications, classified as GLP-1 receptor agonists, achieve their therapeutic effects by delaying stomach emptying, creating sustained satiety. While this mechanism effectively manages blood sugar and supports weight reduction, extended use has allegedly led to unexpected and severe health complications for some patients.
Dental damage has emerged as a particularly concerning issue. Multiple plaintiffs report that chronic vomiting induced by these medications has eroded their tooth enamel, resulting in significant tooth loss. In one notable case, a patient’s persistent vomiting led to extensive dental damage and required multiple hospitalizations.
The lawsuits also highlight cases of gastroparesis, a debilitating condition where the stomach loses its ability to properly process food. Affected patients describe intense physical discomfort and nutritional challenges, with some cases severe enough to require emergency medical intervention.
While both pharmaceutical companies maintain that their product labels adequately communicate potential gastrointestinal risks, plaintiffs contend that these warnings understate the potential severity of side effects. Legal analysts anticipate more lawsuits will emerge, potentially prompting regulatory changes and enhanced warning requirements. This growing controversy leaves current users balancing the medications’ proven benefits against increasingly documented risks of serious complications.
